Heparan sulfate-binding proteins (HS-BPs)

Heparan sulfate-binding proteins encompass a diverse group of extracellular matrix (ECM) components and growth factors that interact with heparan sulfate (HS) glycosaminoglycans (Bishop et al., 2007, Nature). These interactions occur at specific basic amino acid clusters known as HS-binding sites, which facilitate the sequestration, protection, and presentation of ligands to their signaling receptors (Ori et al., 2008, Frontiers in Bioscience). Key members include fibroblast growth factors (FGFs), vascular endothelial growth factors (VEGFs), and ECM proteins like fibronectin and laminin (Nader et al., 2004, Glycoconjugate Journal). In diseases such as cancer, the dysregulation of these interactions—often via heparanase-mediated cleavage—promotes tumor growth, angiogenesis, and metastasis (Dredge et al., 2003, British Journal of Cancer). Therapeutic interventions, including heparin mimetics like muparfostat, aim to competitively occupy these binding sites to disrupt pathological signaling cascades (Zhou et al., 2020, Frontiers in Oncology). However, targeting these sites presents challenges due to the broad biological roles of HS, potentially leading to off-target effects such as bleeding or impaired tissue repair (Sasisekharan et al., 2006, Nature Reviews Cancer). The complexity of the HS-interactome requires highly specific agents to avoid systemic toxicity while effectively inhibiting localized disease processes. Monitoring biomarkers like heparanase expression or circulating syndecan-1 levels can help in assessing the therapeutic efficacy of HS-targeted drugs.

Other names

Heparin-binding proteinsHS-binding growth factorsECM-associated HS-binding proteinsHeparan sulfate-binding extracellular matrix proteins

Competitive inhibition of the interaction between heparan sulfate proteoglycans and their protein ligands (growth factors and ECM proteins) to modulate signaling and bioavailability.